Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

157 results about "Pancreatic lipase" patented technology

Pancreatic lipase, also known as pancreatic triacylglycerol lipase, is secreted from the pancreas, and is the primary lipase that hydrolyzes dietary fat molecules in the human digestive system, converting triglyceride substrates found in ingested oils to monoglycerides and free fatty acids. Triacylglycerol + 2 H₂O 2-monoacylglycerol + 2 fatty acid anions Bile salts secreted from the liver and stored in gallbladder are released into the duodenum, where they coat and emulsify large fat droplets into smaller droplets, thus increasing the overall surface area of the fat, which allows the lipase to break apart the fat more effectively. The resulting monomers are then moved by way of peristalsis along the small intestine to be absorbed into the lymphatic system by a specialized vessel called a lacteal. This protein belongs to pancreatic lipase family. Unlike some pancreatic enzymes that are activated by proteolytic cleavage, pancreatic lipase is secreted in its final form. However, it becomes efficient only in the presence of colipase in the duodenum. In humans, pancreatic lipase is encoded by the PNLIP gene.

Application of mangiferin compound or mango extraction as pancreatic lipase inhibitor and to preparation of medicament or food for preventing and treating obesity

The invention provides an application of a mangiferin compound with a structure shown as a formula I as a pancreatic lipase inhibitor, an application of a mango extract containing the mangiferin compound with the structure shown as the formula I as a pancreatic lipase inhibitor, and an application of the mangiferin compound with the structure shown as the formula I or the mango extract containing the mangiferin compound with the structure shown as the formula I to preparation of a medicament or a food for treating and/or preventing obesity, and provides an application of the mangiferin compound with the structure shown as the formula I or the mango extract containing the mangiferin compound with the structure shown as the formula I to preparation of a medicament or a food for treating and/or preventing obesity. The mangiferin compound has the function of inhibiting the activity of pancreatic lipase, so that the occurrence of obesity can be avoided by inhibiting the accumulation of in-vivo fat. Meanwhile, the mangiferin compound has wide physiological activity, so that side effects on human bodies caused by the conventional weight-losing product can be avoided.
Owner:HAINAN LIYAOTANG BIOTECH DEV

Phytomedicinal compositions for the control of lipid accumulation and metabolism in mammals

InactiveUS20050271755A1BiocideUnknown materialsHormone-sensitive lipaseSolvent
A method of producing a phytomedicinal therapeutic for the prevention and control of a disease selected from the group consisting of obesity, cardiovascular disease, and diabetes, and conditions related thereto is provided which comprises extracting peanut shells with a solvent, removing a substantial portion of the solvent to produce a concentrated extract. Phytomedicinal compositions are provided that comprise an effective amount of at least one coumarin compound or one coumarin derivative derived from plant material that modulates a biological activity of at least one enzyme selected from the group consisting of Pancreatic Lipase (PL), Lipoprotein Lipase (LPL), and Hormone-Sensitive Lipase (HSL). Phytomedicinal compositions are provided that comprise at least an effective amount of coumarin derivatives (6,7-dihydroxycoumarin-esculetin, and esculetin-like compounds). A method for the prevention and/or treatment of treatment of a condition selected from the group consisting of obesity, cardiovascular disease, and diabetes, is provided which comprises administering a composition comprising an effective amount of at least one coumarin derivative, including 6,7-dihydroxycoumarin (esculetin), derived from plant material that modulates a biological activity of at least one enzyme selected from the group consisting of Pancreatic Lipase (PL), Lipoprotein Lipase (LPL), and Hormone-Sensitive Lipase (HSL).
Owner:RUTGERS THE STATE UNIV

Mesoporous biomaterial containing porcine pancreatic lipase and preparation method of mesoporous biomaterial

InactiveCN102676493ARegular one-dimensional channel structureLarge specific surface areaOn/in inorganic carrierWater bathsNano biosensor
The invention discloses a mesoporous biomaterial containing porcine pancreatic lipase and a preparation method of the mesoporous biomaterial. The method comprises the steps of dissolving surfactant in water solution of hydrochloric acid, adding inorganic silicon source and organic silylating reagent, fully hydrolyzing under a water bath condition, aging, cooling, filtering, washing, drying and extracting the surfactant to obtain mesoporous silica containing an active group, then putting the prepared material into buffer solution of porcine pancreatic lipase, centrifuging, filtering and drying to obtain the mesoporous biomaterial with functionalized porcine pancreatic lipase. The method disclosed by the invention is simple and environment-friendly. The synthetic mesoporous biomaterial containing the porcine pancreatic lipase has the characteristics of large aperture, high specific surface area, high enzyme activity and large enzyme activity increasing proportion, and can be directly used as biological catalytic material. The mesoporous biomaterial containing the porcine pancreatic lipase disclosed by the invention has wide application prospect in these respects of not only bioreactors, but also nano-bio-sensors, biomolecular delivery and the like.
Owner:NANJING UNIV OF TECH

Chinese and western composite medicine for treating neoplastic diseases

A Chinese and western composite medicine for treating neoplastic diseases is characterized by comprising Chinese herbal medicinal ingredients and a western medicinal ingredient which are mixed, the Chinese herbal medicinal ingredients include 5 polyzyme tablets and a stomach invigorating and digestion aiding tablet, each polyzyme tablet comprises pepsin, trypsin, pancreatic lipase and amylopsin, and the stomach invigorating and digestion aiding tablet comprises radix pseudostellariae, tangerine peels, Chinese yam, (roasted) malt and hawthorn; the western medicinal ingredient is ceftriaxone sodium injection solution; and the weight of each polyzyme tablet is 0.313g, the total weight of the polyzyme tablets is 1.57g, the weight of the stomach invigorating and digestion aiding tablet is 0.8g, the weight of the ceftriaxone sodium injection solution is 0.75g, and the Chinese herbal medicinal ingredients and the western medicinal ingredient are combined to form the prescription. The Chinese and western composite medicine for treating the neoplastic diseases is particularly used for suppressing and killing pathogenic bacteria capable of causing benign tumor and malignant tumor infection of tissue cells of a human body, the composite medicine is directly dripped into the oral cavity or an affected part of the human body when the human body suffers from the tumor infection, and 3-4 drops of the composite medicine are applied every time. The Chinese and western composite medicine has few side effects, becomes effective within 30 minutes and does not injure the liver, the brain and the kidneys of the human body.
Owner:李红彬
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products